trending Market Intelligence /marketintelligence/en/news-insights/trending/yqdojkdaxau2rttgvbn-va2 content esgSubNav
In This List

Aileron Therapeutics' chief medical, scientific officer becomes CEO

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Aileron Therapeutics' chief medical, scientific officer becomes CEO

Aileron Therapeutics Inc. appointed Manuel Aivado as president and CEO.

Aivado succeeds John Longenecker, who replaced Joseph Yanchik III on an interim basis after he resigned.

Aivado has been the senior vice president and chief medical and scientific officer of the biopharmaceutical company since 2012. He most recently designed and implemented the first-in-human trial of the company's experimental anti-tumor therapy ALRN-6924.